Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ImaRx Therapeutics Inc.

Division of Cerevast Medical Inc.

Latest From ImaRx Therapeutics Inc.

Ischemic Stroke: Prying Open the Treatment Window

At this year's International Stroke Conference in San Antonio, some exciting device-based therapies and approaches were discusssed--including advanced imaging, multimodal therapy and stent-like thrombectomy devices--that may offer improved outcomes for patients that suffer an acute ischemic stroke.

Medical Device

Valuation Watch: Anti-Infectives a Rare Bright Spot for Last Crop of Biotech IPOs

Most of the 15 biotech IPOs in the US in 2007 have performed poorly on the public markets. There have been exceptions: Sirtris was acquired by GSK at a significant premium to its IPO price. And anti-infectives focused biotechs Pharmasset and Optimer have outclassed their peers as they have outperformed the market.

BioPharmaceutical Business Strategies

Stroke Devices: Facing Challenges Head On

The International Stroke Conference, held in San Diego in February 2009, presented several device-based therapies and approaches that could offer improved outcomes for patients that suffer an acute ischemic stroke. The technologies discussed included mechanical thrombectomy devices, laser treatments, and combined therapy using ultrasound, microspheres, and thrombolytic drugs.

Medical Device

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008

Highlights from the Q2 2008 review of pharmaceutical and biotechnology dealmaking: Despite the dearth in biopharmaceutical financings in the quarter (total money raised was just $2 billion) acquisitions thrived with total M&A volume of $11.8 billion. And biopharma alliance activity reached $2.7 billion in potential deal value during 2008's second quarter with only a handful more deals than the first quarter, but a 43% increase in dollar volume.

See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cerevast Medical Inc.
  • Senior Management
  • Bradford A Zakes, Pres. & CEO
    Greg A Cobb, CFO
    Jennifer Marshall, VP, Corp. Dev.
    Garen Manvelian, CMO
  • Contact Info
  • ImaRx Therapeutics Inc.
    Phone: (520) 770-1259
    1730 E. River Rd.
    Ste. 200
    Tucson, AZ 85718